Beam Therapeutics
BEAM
205 hedge funds and large institutions have $2.09B invested in Beam Therapeutics in 2022 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 91 increasing their positions, 45 reducing their positions, and 59 closing their positions.
102% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 45
6.19% more ownership
Funds ownership: 71.62% → 77.81% (+6.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
15% less funds holding
Funds holding: 240 → 205 (-35)
26% less capital invested
Capital invested by funds: $2.82B → $2.09B (-$732M)
35% less call options, than puts
Call options by funds: $11.4M | Put options by funds: $17.5M
54% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 59
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$53.9M |
| 2 |
BlackRock
New York
|
+$44.4M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$34.9M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$23.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$26.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$24.4M |
| 3 |
CC
Casdin Capital
New York
|
-$17.6M |
| 4 |
Millennium Management
New York
|
-$7.06M |
| 5 |
CU
CQS (US)
New York
|
-$5.5M |
BEAM Hedge Fund Activity: Q2 2022 in Review
205 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q2 2022, worth a combined $2.09B — down 26% from $2.82B a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of BEAM and 27 opened new positions — a net loss of 32 holders — while 45 trimmed existing stakes and 91 added.
The largest buyer was State Street, adding an estimated $53.9M. The largest seller was Victory Capital Management, cutting an estimated $26.4M.
- 205 institutional investors held Beam Therapeutics (BEAM) as of Q2 2022, down from 240 in Q1 2022.
- Funds reported $2.09B of Beam Therapeutics stock for Q2 2022, down 26% quarter-over-quarter.
- 27 funds opened new Beam Therapeutics positions in Q2 2022 and 59 closed out, a net change of -32 holders.
- The largest Beam Therapeutics buyer in Q2 2022 was State Street, an estimated $53.9M added.
- The largest Beam Therapeutics seller in Q2 2022 was Victory Capital Management, an estimated $26.4M sold.
Based on aggregated 13F filings for Q2 2022.